Nurix Therapeutics, Inc. (NRIX) Stock Price & How to Invest

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a pivotal Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study planned to begin around mid-2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

The investment picture is that of a platform biotech: Nurix generates only modest collaboration revenue, spends heavily on research, and posts large net losses funded by a sizable cash reserve. In June 2026 it announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across hematology, immunology, and neurology, a multi-billion-dollar deal (in potential milestones) that validates the asset and adds non-dilutive funding. As of February 28, 2026 the company held about $540.7 million in cash and marketable securities, and its market capitalization was roughly $1.6 billion. Returns depend on whether the pivotal trials read out positively, whether bexobrutideg reaches the market, and how the partnership milestones convert into cash, all of which remain uncertain.

As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected pivotal path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.

16 analysts publish price targets on NRIX, averaging $33.12 against a $23.21 price as of August 2026, or +42.7%. The published targets run from $25.00 to $45.00, a moderate spread, and the ratings split 14 buy, 1 hold, 0 sell. Over the last six months there have been 8 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NRIX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Nurix Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bexobrutideg pivotal path. The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The most optimistic published target, $45.00, assumes this works close to its best case.

The case against. As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The most pessimistic target, $25.00, is roughly what NRIX is worth if this bites instead.

Read the full bull and bear case on NRIX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Nurix Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (Q1 FY2026, quarter ended Feb 28 2026): ~$6.3 million
• Revenue (year-ago quarter): ~$18.5 million
• R&D expense (Q1 FY2026): ~$84.1 million
• Net loss (Q1 FY2026): ~$87.2 million (~-$0.79 per share)
• Cash & marketable securities (Feb 28 2026): ~$540.7 million
• Market cap (mid-2026): ~$1.6 billion

Nurix is pre-profit, so traditional metrics like P/E do not apply; the market values it on pipeline potential, partnership economics, and cash runway. Q1 FY2026 revenue fell sharply year over year as certain Sanofi collaboration research terms wound down, while R&D spending drove a wider net loss. The roughly $540 million cash position funds the registrational bexobrutideg program and broader pipeline, though a quarterly burn near $80 million and future trials mean funding and dilution remain key watch items.

Other names that sit close to NRIX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NRIX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NRIX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NRIX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Nurix is a pre-profit, clinical-stage biotech whose stock trades on trial data, partnership economics, and cash runway rather than earnings, so it carries binary clinical risk alongside the upside of a validated protein-degradation platform.

Whether NRIX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NRIX a buy or a sell?, and where the stock could go from here in the NRIX stock forecast.

For income investors, whether NRIX pays a dividend and how the payout looks is covered in does NRIX pay a dividend? And to weigh NRIX against a peer, read the full side-by-side comparisons: NRIX vs PFE and NRIX vs ABBV.